Form 4: Vera Therapeutics CEO Marshall Fordyce Executes Stock Option and Sells Shares
SEC Form 4
Vera Therapeutics CEO Marshall Fordyce exercised stock options and sold shares of Class A Common Stock on August 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On August 28, 2024, Marshall Fordyce, the President and CEO of Vera Therapeutics, executed stock options to acquire 15,625 shares of Class A Common Stock at a price of $2.8968 per share.
- Fordyce also sold a total of 30,320 shares of Class A Common Stock in multiple transactions at weighted-average prices ranging from $36.8001 to $37.5357.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on April 23, 2024.
- Following these transactions, Fordyce directly owns 307,972 shares of Class A Common Stock and 842,962 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports routine transactions by an insider under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 12/16/2021 | 1/4 of the shares subject to the option vested |
| 04/23/2024 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| 08/28/2024 | Date of the stock option exercise and stock sales |
| 08/30/2024 | Date of signature for the Form 4 filing |
| 12/15/2030 | Expiration date of the stock option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.